News & Views | Published:

Spondyloarthropathies

TNF inhibitors and structural damage in ankylosing spondylitis

Nature Reviews Rheumatology volume 14, pages 56 (2018) | Download Citation

Whether TNF inhibitors prevent structural damage in ankylosing spondylitis remains a controversial topic, as three prospective trials failed to show any evidence to support this notion. However, data are accumulating from retrospective analyses of well-characterized cohorts of patients that could provide the solution to this controversy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. (2017).

  2. 2.

    et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).

  3. 3.

    et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063–3070 (2008).

  4. 4.

    et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).

  5. 5.

    et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645–2654 (2013).

  6. 6.

    et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 69, 1011–1019 (2017).

  7. 7.

    et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann. Rheum. Dis. 73, 710–715 (2014).

  8. 8.

    et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann. Rheum. Dis. (2017).

  9. 9.

    et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978–991 (2017).

  10. 10.

    et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis [abstract]. Ann. Rheum. Dis. 69 (suppl 10), 3L (2017).

Download references

Author information

Affiliations

  1. Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.

    • Atul Deodhar

Authors

  1. Search for Atul Deodhar in:

Competing interests

A.D. declares that he has acted on the advisory board for or received research grants from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB.

Corresponding author

Correspondence to Atul Deodhar.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2017.197

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing